Sign inJoin waitlistJoin the waitlist

Patrick M. Reagan

Associate Professor - Department of Medicine, Hematology/Oncology · URochester Medicine

Credentials: · · · ·

History

URochester Medicine
Present

University of Rochester Medical Center
2013–2015
University of Virginia-Radiology GME
2012–2013
University of Virginia-Radiology GME
2010–2012
University of Virginia-Radiology GME
2009–2010
SUNY Upstate College of Health Professions
2009

Research

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
The Lancet Oncology · 2019 · 1,921 citations
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
New England Journal of Medicine · 2020 · Last of 25 authors · 1,512 citations

Jonathan Friedberg
21 papers
FL
Frederick Locke
20 papers
David Miklos
17 papers
Brian Hill
15 papers
JM
Javier Munoz
15 papers
Carla Casulo
14 papers
Caron Jacobsen
14 papers
Olalekan Oluwole
14 papers
AG
Armin Ghobadi
13 papers · 1 as a fellow
Paul Barr
13 papers
Andre Goy
12 papers
Sattva Neelapu
12 papers

Clinical trials

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
Principal investigator · Active not recruiting · Phase 2
University of Rochester
2021–2027
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Principal investigator · Active not recruiting · Phase 2
Patrick Reagan
2016–2025
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2029